Alpharma Eyeing Commercial, Legal Options For Gabapentin Following ANDA Stay
This article was originally published in The Pink Sheet Daily
Executive Summary
The company could seek a settlement with Apotex to dismiss its challenge to Alpharma’s 180-day generic marketing exclusivity for Neurontin, the lifting of the federal appeals court stay of approval or an accelerated hearing date.
You may also be interested in...
Pfizer Asks Court To Keep Purepac’s Neurontin Generic Off The Market
Brand company’s arguments in support of a preliminary injunction could be bolstered by the fact that, unlike Ivax’ product, Purepac’s gabapentin generic is AB-rated and the Alpharma division has said a launch would not hinge on resolution of patent litigation with Pfizer.
Pfizer Asks Court To Keep Purepac’s Neurontin Generic Off The Market
Brand company’s arguments in support of a preliminary injunction could be bolstered by the fact that, unlike Ivax’ product, Purepac’s gabapentin generic is AB-rated and the Alpharma division has said a launch would not hinge on resolution of patent litigation with Pfizer.
Alpharma Seeks To Remove Stay On Generic Neurontin Approval
Company would launch gabapentin capsules "at risk" if stay on approval were lifted. The stay has been imposed because of dispute with Apotex regarding first-to-file exclusivity.